MedTrace Logo

Investigation of Systemic and Regional Haemostasis During Liver Transplantation by Comparing ClotPro® and TEG®

NCT04246307 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-02-07

No results posted yet for this study

Summary

The purpose of the research is to compare the global and the portal haemostasis during liver transplantation by functional investigations using TEG® and ClotPro® tests. The study aims at revealing important coagulation-associated links affecting the outcome of the liver transplant surgery.

Conditions

  • Haemostasis Disorders

Interventions

DIAGNOSTIC_TEST

TEG® and ClotPro® parameters

Systemic sampling is performed six times: * before the surgery (S1) * during the hepatectomy, 10 minutes before the anhepatic phase (S2) * in the anhepatic phase, before starting portal vein anastomosis: (S3) * in the neohepatic phase, 15 minutes after releasing portal vein clamping: (S4) * in the neohepatic phase, at the end of the surgery: (S5) Regional sampling from the portal vein representing afferent flow to the liver is performed once: • in the anhepatic phase, before starting portal vein anastomosis: (R) Simultaneously with haemostasis and blood gas analyses, the following investigations will be performed (the following tests are also routinely performed at the given time points, independently of this study): * haemodynamic measurements by PiCCO * arterial blood gas analysis from radial artery catheter * central venous blood gas analysis from subclavian vein catheter * blood temperature measurement in the femoral artery by PiCCO catheter * hourly urinary output

Sponsors & Collaborators

  • DiaCare Solution Kft

    collaborator UNKNOWN

  • Semmelweis University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-01-01
Completion
2022-01-01

Countries

  • Hungary

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04246307 on ClinicalTrials.gov